- Home
- FMAO vs KMDA Comparison
FMAO vs KMDA Comparison
Compare FMAO & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- KMDA
- Stock Information
- Founded
- FMAO 1897
- KMDA 1990
- Country
- FMAO United States
- KMDA Israel
- Employees
- FMAO N/A
- KMDA N/A
- Industry
- FMAO Savings Institutions
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- KMDA Health Care
- Exchange
- FMAO Nasdaq
- KMDA Nasdaq
- Market Cap
- FMAO 358.1M
- KMDA 392.2M
- IPO Year
- FMAO N/A
- KMDA N/A
- Fundamental
- Price
- FMAO $23.68
- KMDA $6.75
- Analyst Decision
- FMAO
- KMDA Strong Buy
- Analyst Count
- FMAO 0
- KMDA 2
- Target Price
- FMAO N/A
- KMDA $13.00
- AVG Volume (30 Days)
- FMAO 20.6K
- KMDA 71.3K
- Earning Date
- FMAO 10-28-2025
- KMDA 11-12-2025
- Dividend Yield
- FMAO 3.83%
- KMDA 2.97%
- EPS Growth
- FMAO 38.39
- KMDA 27.97
- EPS
- FMAO 2.16
- KMDA 0.32
- Revenue
- FMAO $108,632,000.00
- KMDA $169,517,000.00
- Revenue This Year
- FMAO $3.38
- KMDA $14.49
- Revenue Next Year
- FMAO $6.39
- KMDA $10.12
- P/E Ratio
- FMAO $10.71
- KMDA $19.98
- Revenue Growth
- FMAO 13.86
- KMDA 9.67
- 52 Week Low
- FMAO $20.88
- KMDA $5.18
- 52 Week High
- FMAO $34.15
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- FMAO 41.51
- KMDA 46.25
- Support Level
- FMAO $22.89
- KMDA $6.60
- Resistance Level
- FMAO $25.06
- KMDA $7.05
- Average True Range (ATR)
- FMAO 0.92
- KMDA 0.17
- MACD
- FMAO -0.16
- KMDA 0.01
- Stochastic Oscillator
- FMAO 31.16
- KMDA 45.45
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.